TNF and atherosclerosis: The result of the trial also implicates that targeting other inflammatory pathways, such as the ones mediated by interlukin-6 or tumor necrosis factor alpha (TNFα) (83), can display therapeutic benefits, yet the molecular mechanisms behind how inflammation is initiated in atherosclerosis remains controversial (1).